MARKET NEWS

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients With Krabbe Disease
FDA Approves New Treatment Option for Patients With ALS
Evonik & Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan

  FEATURED EDITORIAL

  COMPANY PROFILE

Lonza CHI is a preferred global partner to the pharmaceutical, biotech and nutraceutical markets. ​Our pioneering Capsugel® capsules and encapsulation technologies help improve speed of development and execution and the match of dosage form performance to ingredients or API application. Our product portfolio and product services for pharmaceutical partners include capsules (including customizations), equipment, and ingredient/API formulation services. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Pistoia Alliance Launches Global Community of Interest to Assess the Environmental Impact of Clinical Trials

Pistoia Alliance Launches Global Community of Interest to Assess the Environmental Impact of Clinical Trials

The Pistoia Alliance recently announced the launch of the Clinical Trials Environmental Impact Community of Interest (CoI) to measure and compare the carbon footprint of centralized (traditional site-based) and decentralized clinical trials…..

VBI Vaccines & Agenus Announce Collaboration to Evaluate VBI-1901 in Combination With Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

VBI Vaccines & Agenus Announce Collaboration to Evaluate VBI-1901 in Combination With Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

VBI Vaccines Inc. and Agenus recently announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal….

Tavros Therapeutics & Vividion Therapeutics Announce Strategic Collaboration to Discover & Enhance Targeted Oncology Programs

Tavros Therapeutics & Vividion Therapeutics Announce Strategic Collaboration to Discover & Enhance Targeted Oncology Programs

Tavros Therapeutics and Vividion Therapeutics, Inc. recently announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term…..

Syneos Health Expands Partnership With Datavant to Accelerate Delivery of New Therapies to Patients

Syneos Health Expands Partnership With Datavant to Accelerate Delivery of New Therapies to Patients

Syneos Health recently announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

WHITEPAPER - Launching a Drug-Device Combination: 5 Key Factors to Focus On

WHITEPAPER - Launching a Drug-Device Combination: 5 Key Factors to Focus On

In today’s fast-growing biopharma market, injectable medications have become a powerful driver of growth and innovation. Within that sector, industry leaders are increasingly focused on one key area: integrating a drug product and a delivery device. As the market expands …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 26 – Formulation Development
November 2 – Prefilled Syringes